This is a preview of subscription content, log in via an institution to check access.
REFERENCES
Abrahamov A, Elstein D, Gross-Tsur V, et al (1995) Gaucher's disease variant characterized by progressive calcification of heart valves and unique genotype, Lancet 346: 1000-1003.
Beutler E, Grabowski GA (1995) Gaucher disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 2641-2670.
Bove KE, Daugherty C, Grabowski GA (1995) Pathological findings in Gaucher disease type 2 patients following enzyme therapy. Hum Pathol 26: 1040-1045.
Czartoryska B, Tylki-Szymanska A, Lugowska A (2000) Changes in serum chitotriosidase activity with cessation of replacement therapy (cerebrosidase) administration in Gaucher disease. Clin Biochem 33: 147-149.
Elstein D, Abrahamov A, Zimran A (1998) Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease. Clin Genet 54: 79-184.
Erikson A (1986) Gaucher disease—Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand Suppl 326: 1-42.
Erikson A, Johansson K, Månsson J-E, Svennerholm L (1993) Enzyme replacement therapy of infantile Gaucher disease. Neuropediatrics 24: 237-238.
Erikson A, Bembi B, Schiffmann R. (1997) Neuronopathic forms of Gaucher's disease Ballière's Clin Hematol 10: 711-723.
Harris CM, Taylor DSI, Vellodi A (1999) Ocular motor abnormalities in Gaucher disease. Neuropediatrics 30: 289-293.
Ida H, Rennert OM, Iwasawa K, Kobayashi M, Eto Y (1999) Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Hum Genet 105: 120-126.
Kyllerman M, Conradi N, Månsson JE, Percy AK, Svennerholm L (1990) Rapidly progressive type III Gaucher disease: deterioration following partial splenectomy. Acta Paediatr Scand 79: 448-453.
Patterson MC, Horowitz M, Abel RB, et al. (1993) Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher disease. Neurology 43: 1993-1997.
Prows CA, Sanchez N, Daugherty C, Grabowski GA (1997) Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 71: 16-21.
Ringden O, Groth CG, Erikson A, Granqvist S, Mansson JE, Sparrelid E (1995) Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation 59: 864-870.
Schiffmann R, Heyes MP, Aerts JM, et al (1997) Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann Neurol 42: 613-621.
Tylki-Szymanska A, Millat G, Maire I, Czartoryska B (1996) Types I and III Gaucher disease in Poland: incidence of the most common mutations and phenotypic manifestations. Eur J Hum Genet 4: 334-337.
Uchiyama A, Tomatsu S, Kondo N, et al (1994) New Gaucher disease mutation in exon 10: a novel L444R mutation produces a new NciI site the same as L444P. Hum Mol Genet 3: 1183-1189.
Vellodi A, Young E, Harris C (1999) The management of children with neuronopathic Gaucher disease; a single-centre experience. Abstracts of the Third EWGGD Workshop, Lemnos, p. 68.
Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E (1989) Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet 2: 349-352.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vellodi, A., Bembi, B., de Villemeur, T.B. et al. Management of neuronopathic Gaucher disease: A European consensus. J Inherit Metab Dis 24, 319–327 (2001). https://doi.org/10.1023/A:1010514614570
Issue Date:
DOI: https://doi.org/10.1023/A:1010514614570